Chapter 795

It's not just grace who pays close attention to the research progress of Huarui laboratory, but also Jericho, as well as pharmaceutical companies from Japan and Norway.

After discovering that the number of candidate compounds in Huarui laboratory has declined rapidly, several companies have inquired about the situation.

8 The two candidate compounds are considered as an important node. If the decline is due to safety and other technical reasons, it means that the compound is likely to fail animal experiments, but on the contrary, it means that there is a lot of room for selection.

Abundant choice space means that the cost may be greatly reduced.

Yang Rui made more than 30 kinds of compounds in one breath. Naturally, the synthetic routes adopted by him are various, and some of them are unimaginable with normal thinking.

Nevertheless, most of the more than 30 compounds use expensive raw materials or catalysts.

It's not that expensive raw materials or catalysts can't be used in drugs. The key to the problem is profit.

These companies focus on coenzyme Q10 catalyst formulation for profit, and focus on deferonone for profit as well.

Moreover, compared with the catalyst formula of coenzyme Q10, the grade of deferonone is much higher.

A new drug, for a super large company like Pfizer, is also a few core projects every year. For ordinary medium and large pharmaceutical enterprises, it often represents a fraction of the company's assets.

In short, if a pharmaceutical company can produce a new drug, it will rank among the pharmaceutical companies in the world.

Although there are tens of thousands or even more pharmaceutical companies in the world, 99% of them are generic drug companies.

Generic drug companies are not necessarily weak, but original drug companies are certainly strong, whether they are strong in strength, laboratory or spirit, because the strong strength, laboratory and spirit brought by a new drug may turn into money in the future.

Every year, more than half of the dozens of new drugs in the world, half plus half, and half plus half, belong to multinational pharmaceutical companies.

The rest belong to small and medium-sized pharmaceutical enterprises, there is not necessarily one in a year.

It's a very risky business.

However, there are still people who continue to invest in it.

Jerichon is a multinational pharmaceutical company with annual sales of more than 10 billion US dollars. However, the number of new drugs they can add each year is also very limited, usually hovering around three kinds.

Deferonone may not be a blockbuster, but who knows?

Many drugs developed new indications only after they were put on the market, and then they became aviation bombs with a marketing value of 10 billion.

Therefore, people who originally focused on coenzyme Q10 catalyst also inevitably focused on deferonone, which is very successful in animal experiments.

However, Yang Rui did not agree to the visit of jerichon and other companies, let alone Japan and Norway.

He didn't even let grace know the details of his experiment, only the briefing came out of the small compartment and appeared in front of others in the morning report.

So, in the next two days, Yang Rui removed a compound again, and then ended his independent work in the laboratory.

The remaining seven compounds are not at great risk. In fact, they may be used as finished products of deferrone, and several of them appear as generic drugs. Naturally, there is not much safety problem.

Yang Rui just step by step, let them finish the animal experiment.

And the closer to completion, the more curious companies such as Jericho are.

At this stage, they are really just curious.

However, this kind of curiosity also makes their heart itch.

On the third day after Yang Rui screened out the last seven compounds, Frankie came to Peking University with a group of people.

The so-called run monk can't run temple, people find Peking University, Yang Rui really can't run away.

Not only can't run away, but also can't keep a low profile.

When a group of foreigners come to school, we must pay attention to them.

When Yang Rui received the call and came outside to meet people, President Liu also ran out.

"Oh, so many international friends come to visit our school. Why don't you say, Yang Rui? What's the purpose of this time?" President Liu said something like complaining. His eyes were as bright as a monkey.

"For the research of Ferrone in Huarui laboratory." Yang Rui explained in one sentence.

President Liu naturally knew about it. "Oh," he said, "it's all for this medicine, isn't it that we don't make money?""It won't make money in the short term, not necessarily in the long term." Yang Rui then said: "how to say it's all an original drug, and more patents for original drugs will bring a lot of benefits."

"It's like the shark smelling fishy again?" President Liu nodded with understanding.

Yang Rui laughed: "it's not that serious. It's the animal experiment stage. They can't make money even if they take it."

There are tens of millions of drugs that pass animal experiments every year, but only a few of them are valuable.

"What's that for?" President Liu's attitude has changed rapidly.

"Still smell fishy, just don't see meat, it's estimated that it won't be too fierce."

Yang Rui went back with President Liu to entertain representatives of foreign companies from afar.

With the canteen director, all the way to ask: "do you want to open a private room, what do we give them to eat?"

"Just eat the papers." Yang Rui's answer was crisp. When he got to the place, he fed a group of people a pile of documents.

Arnold and others enjoyed it so much that they quickly looked through it. Grace was the first to grab it and said, "it's too thin."

"When you get back to the lab, I'll give you a thickened version." Yang Rui said with a smile that he was willing to work in vain. He should be given some privileges.

Grace seemed quite satisfied, but the change of her expression was very weak. She just looked at the information.

Arnold was chanting beside, comparing the completion of various aspects of animal experiments one by one.

Clinical candidate compounds have some landmark characteristics. The more these characteristics are, the more necessary it is to conduct clinical trials.

Jerichon is a multinational company that often does mergers and acquisitions. It has its own method. By scoring these characteristics, it can judge the approximate value of a compound.

Frankie next to help Arnold quietly calculate, said: "the animal model is effective, no genetic toxicity, no acute and chronic toxicity, the basic 15 points can be obtained."

"The target of action has been verified in clinic. Iron chelator is very simple. Let's count it as 3 points. There is a competitive advantage, but can it be better than deferoxamine? "

"Two, five in all."

"That's 20 points. In terms of raw materials and costs, these compounds are different... Let's see, we can basically get five points. 25 points? " Arnold took a sniff.

Jielikang's calculation formula is simple and complex, but it has never been based on 60 points. As for the formula they use now, if they can reach 30 points, it is a rare high score. Companies usually contact and try to acquire it.

Frankie looked down at the file and said, "seven back-up compounds, at least 10 points?"

"Well... Their animal experiments have not been completed yet. I don't think we should forget about the item of backup compounds. Who knows how many of them can pass in the end." Arnold didn't want to give a 35.

French indifferent way: "because it is a rare disease drugs, there are seven years of drug monopoly period, do you want to add points?"

Arnold hesitated for a moment, and said: "even so, rare diseases mean low sales. If monopoly is to make up for the lack of sales... Count 3 points."

Although it was only a private estimate, he was embarrassed that it was too unfair.

"That's 28," said Frankie

"Well..." Arnold looked at the next row of items that hadn't been calculated. There was some tartaric acid.